MX2023008182A - Aglutinantes de herv-h asociado a ltr 2 (hhla2) con actividad novedosa. - Google Patents

Aglutinantes de herv-h asociado a ltr 2 (hhla2) con actividad novedosa.

Info

Publication number
MX2023008182A
MX2023008182A MX2023008182A MX2023008182A MX2023008182A MX 2023008182 A MX2023008182 A MX 2023008182A MX 2023008182 A MX2023008182 A MX 2023008182A MX 2023008182 A MX2023008182 A MX 2023008182A MX 2023008182 A MX2023008182 A MX 2023008182A
Authority
MX
Mexico
Prior art keywords
hhla2
herv
ltr
novel activity
binders
Prior art date
Application number
MX2023008182A
Other languages
English (en)
Spanish (es)
Inventor
Nels Nielson
Scott Chappel
Nadthakarn Boland
Bianka Prinz
Detlev Biniszkiewicz
Bijan Etemad-Gilbertson
Original Assignee
Nextpoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextpoint Therapeutics Inc filed Critical Nextpoint Therapeutics Inc
Publication of MX2023008182A publication Critical patent/MX2023008182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
MX2023008182A 2021-01-28 2022-01-28 Aglutinantes de herv-h asociado a ltr 2 (hhla2) con actividad novedosa. MX2023008182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163142832P 2021-01-28 2021-01-28
PCT/US2022/014423 WO2022165258A1 (en) 2021-01-28 2022-01-28 Hhla2 binding agents with novel activity

Publications (1)

Publication Number Publication Date
MX2023008182A true MX2023008182A (es) 2023-09-15

Family

ID=82652818

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008182A MX2023008182A (es) 2021-01-28 2022-01-28 Aglutinantes de herv-h asociado a ltr 2 (hhla2) con actividad novedosa.

Country Status (11)

Country Link
US (1) US20250270323A1 (enExample)
EP (1) EP4284431A4 (enExample)
JP (2) JP2024509501A (enExample)
KR (1) KR20230135637A (enExample)
CN (1) CN116981476A (enExample)
AU (1) AU2022214939A1 (enExample)
BR (1) BR112023014826A2 (enExample)
CA (1) CA3207494A1 (enExample)
IL (1) IL304584A (enExample)
MX (1) MX2023008182A (enExample)
WO (1) WO2022165258A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122161832A (zh) * 2023-09-08 2026-06-05 Nextpoint治疗公司 抗体-药物缀合物
CN119841949B (zh) * 2023-10-17 2026-06-05 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015167948A1 (en) * 2014-04-30 2015-11-05 Albert Einstein College Of Medicine Of Yeshiva University Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
TWI917306B (zh) * 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
MX2020010094A (es) * 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途

Also Published As

Publication number Publication date
KR20230135637A (ko) 2023-09-25
JP2024509501A (ja) 2024-03-04
WO2022165258A1 (en) 2022-08-04
BR112023014826A2 (pt) 2023-10-03
EP4284431A4 (en) 2025-01-15
IL304584A (en) 2023-09-01
EP4284431A1 (en) 2023-12-06
JP2026119212A (ja) 2026-07-16
US20250270323A1 (en) 2025-08-28
CN116981476A (zh) 2023-10-31
CA3207494A1 (en) 2022-08-04
AU2022214939A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CL2021003580A1 (es) Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso
ECSP21056325A (es) Compuesto heterocíclico y su uso
EP3950716A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES AND USE THEREOF
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
UY38713A (es) Arilamidinas fungicidas
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
TR200102799T2 (tr) Kemokin alıcı bağlayıcı heterosiklik bileşikler
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
MX385269B (es) Compuesto de sulfonamida o sal del mismo.
UA47115S (uk) 1. ремінець для смартгодинника
CO2021012807A2 (es) Compuestos de neuregulina-4 y métodos de uso
BR112022013878A2 (pt) Anticorpos que ligam integrina avb8 e utilizações dos mesmos
TWD203576S (zh) 砧板
BR112023014826A2 (pt) Agentes de ligação de hhla2 com nova atividade
EA202191755A1 (ru) Фунгицидная смесь
TN2020000157A1 (en) Binding molecule having neutralizing activity against middle east respiratory syndrome coronavirus
PH12022550765A1 (en) Binding molecule specific for lif and use thereof
BR112022000005A2 (pt) Agentes de ligação a cd38 e usos dos mesmos
MX393753B (es) Nuevo compuesto derivado de la alulosa
JP1704673S (ja) 缶
BR112021025264A2 (pt) Fenoxifenil hidróxi-isoxazolinas e análogos como novos agentes antifúngicos
TR201903631A2 (tr) Sağlikli bi̇reylerde ve poli̇ki̇sti̇k over sendromunda (pkos) yeni̇ over rezervi̇ beli̇rteci̇ olarak mi̇dki̇n protei̇ni̇
TR2022017167U4 (tr) Emzi̇rme örtüsü eklenti̇li̇ emzi̇rme gi̇ysi̇si̇
TR2023005020U4 (tr) Temi̇zleme pedi̇